Medtronic (NYSE: MDT) Poised for Growth: Analyst Upgrade, Strong Revenue, and Dividend King Status

• Analyst firm BTIG raised its price target for Medtronic (NYSE: MDT) to $100.00, maintaining a "Buy" rating, reflecting confidence in its healthcare technology leadership.
• Medtronic reported strong Q1 FY2027 revenue of $9.76 billion, driven by broad demand, leading to an increased financial outlook.
• The company is investing over $700.00 million in Heart Tech and Robotics, alongside a dividend yield over 3.00%, positioning it for durable growth and potential "Dividend King" status.

On September 1, 2026, analyst firm BTIG confirmed its "Buy" rating for Medtronic (NYSE: MDT), increasing its price target to $100.00 from $91.00. Medtronic is a global healthcare technology leader that develops and manufactures medical devices and therapies. The company operates across various segments, including cardiovascular, medical-surgical, neuroscience, and diabetes.

This positive analyst view aligns with strong company performance. For its first quarter of fiscal year 2027, Medtronic reported worldwide revenue of $9.76 billion, as highlighted by PR Newswire. This result, driven by broad demand, led the company to raise its financial outlook for the rest of the year.

The company's growth is supported by significant new investments. As highlighted by The Wall Street Journal, Medtronic is investing over $700.00 million into its Heart Tech and Robotics divisions. This focus on innovation and newer growth platforms is a key part of its strategy to deliver durable growth and serve more patients.

For investors, Medtronic presents value through its dividend, which yields over 3.00%. The company is also close to becoming a 'Dividend King,' a status given to companies with 50 straight years of dividend increases. This consistency attracts long-term investors, such as California’s State Retirement Fund, which holds a 12.00% stake in the company.